<DOC>
	<DOCNO>NCT02493465</DOCNO>
	<brief_summary>This prospective , open label , single-center study , kidney transplant recipient stable renal function 12 120 month transplantation , use use calcineurin inhibitor , azathioprine , prednisone . The prevalence leave ventricular hypertrophy investigate conversion azathioprine everolimus . This study evaluate primary objective : prevalence leave ventricular mass hypertrophy renal transplant recipient azathioprine therapy . And assess ability everolimus reduce leave ventricular mass conversion Azathioprine , use sensitive method MRI . And secondaries objective : Renal function ( measure GFR ) 3 6 12 month conversion , number severity episodes acute rejection proven biopsy , proteinuria 3 , 6 12 month conversion .</brief_summary>
	<brief_title>Effects Everolimus Left Ventricular Hypertrophy After Conversion From Azathioprine : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Hypertrophy , Left Ventricular</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<criteria>Age ≥ 18 year ( black white subject ) ; Kidney transplant recipient live donor decease creatinine clearance ( measure / estimate ) &gt; 50 ml /L least 12 month , receive azathioprine without calcineurin inhibitor without prednisone . The subject , opinion investigator , able complete study protocol ; Multiple organ transplant recipient ; Pregnant woman Breastfeeding childbearing age without contraceptive method Test Positive immunodeficiency virus ( HIV ) Treatment acute rejection last 3 month Glomerulonephritis new relapse New polyomavirus nephropathy protein / creatinine ≤ 150 mg / mmol 24h proteinuria &gt; 500mg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>everolimus</keyword>
	<keyword>leave ventricular hypertrophy</keyword>
</DOC>